Pemigatinib is a drug used to treat cholangiocarcinoma. It does this by stopping the FGFR signaling pathway when there’s an FGFR2 fusion. The drug comes in three tablet strengths: 4.5mg, 9mg, and 13.5mg.
The usual amount you’d take is 13.5 mg every day for 14 days in a row, all in a 21-day period. Each pack has 14 tablets, so you’ve got a full 21-day treatment with one pill a day. It really works well at stopping FGFR2 fusions, which is a mutation in cholangiocarcinoma.
This helps keep the tumor growth in check.
